 Applied Therapeutics, Inc. APLT, a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that three abstracts have been selected, including one oral presentation, at the upcoming American Diabetes Associations ADA 80th Scientific Sessions: A Virtual Experience taking place June 12-16, 2020. The abstracts and presentation include data on the safety and tolerability of Applied Therapeutics investigational candidate for Diabetic Cardiomyopathy DbCM, AT-001, a next generation aldose reductase inhibitor ARI. 